Approximately 73.7% (14/19) of HCC patients with BCLC stage B and C as well as 76.5% (13/17) HCC patients with PVTT had a lower TARBP2 expression (Table S2), demonstrating that TARBP2 deficiency might drive HCC progression. This evidence concerns the gene TARBP2 and hepatocellular carcinoma.